Gilead Sciences: Caution After A Re-Rating Amidst New Concentration Risks

The Value InvestorInvesting Group LeaderFollow5ShareSavePlay(8min)CommentsSummaryGilead Sciences has experienced a significant valuation re-rating, now trading at 16-17x earnings after doubling from 2024 lows.Gilead's growth is increasingly concentrated in its HIV franchise, now nearly three-quarters of product revenue, raising dependency and concentration risks.Recent M&A activity, including the $7.8B Arcellx and $1.675B Ouro deals, aims to diversify, but their impact on revenue remains uncertain.I have exited my position due to demanding valuations and lack of diversified growth, despite strong dividend payouts and manageable leverage.Looking for more investing ideas like this one? Get them exclusively at Value In Corporate Events. Learn More » Michael Vi/iStock Editorial via Getty Images Shares of Gilead Sciences (GILD) have been on a major run higher in recent years, far outperforming many peers that have been struggling. This made sense, as Gilead traded at very low valuations from theThis article was written byThe Value Investor27.71K FollowersFollowThe Value Investor has a Master of Science with specialization in financial markets and a decade of experience tracking companies via catalytic company events. As the leader of the investing group Value In Corporate Events they provide members with opportunities to capitalize on IPOs, mergers & acquisitions, earnings reports and changes in corporate capital allocation. Coverage includes 10 major events a month with an eye towards finding the best opportunities. Learn more.Analyst’s Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article. Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.